Phase 2 Study Synopsis (OBX-319)

Document ID: CSR-201
Version: 1.0
Change History: 1.0 — Initial issue.
Standard(s): ICH E3

Supporting Study — Phase 2 Synopsis — OBX-319

Synopsis of the Phase 2 dose-ranging study of OBX-319 in Systemic Lupus Erythematosus (moderate-to-severe active), establishing the dose(s) and endpoints carried into the pivotal study OBX319-301.